search
Back to results

TURBt With Adjuvant Cryoablation to Treat Bladder Cancer

Primary Purpose

Urinary Bladder Neoplasms

Status
Unknown status
Phase
Not Applicable
Locations
Study Type
Interventional
Intervention
Cryoablation
Epirubicin
Sponsored by
Huashan Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Urinary Bladder Neoplasms focused on measuring Bladder Cancer, Cryoablation

Eligibility Criteria

18 Years - 85 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Clinically diagnosed bladder tumor, stage T1 or T2
  • Number of lesions ≤ 3
  • Tumor size ≤ 3cm

Exclusion Criteria:

  • With other malignant diseases
  • T3 or above
  • Enlarged pelvic lymph node or distant metastasis
  • Poor overall condition

Sites / Locations

    Arms of the Study

    Arm 1

    Arm 2

    Arm Type

    Experimental

    Active Comparator

    Arm Label

    TUR with Cryoablation

    TUR with instant instillation

    Arm Description

    Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.

    Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.

    Outcomes

    Primary Outcome Measures

    Residual tumor rate
    The investigators would perform reTUR 4-6 weeks after initial surgery to detect residual tumor

    Secondary Outcome Measures

    Indwelling time
    Adverse event rate

    Full Information

    First Posted
    April 22, 2016
    Last Updated
    October 17, 2017
    Sponsor
    Huashan Hospital
    Collaborators
    Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Zhongshan Hospital, Shanghai 5th People's Hospital, Zhejiang Provincial People's Hospital
    search

    1. Study Identification

    Unique Protocol Identification Number
    NCT02760953
    Brief Title
    TURBt With Adjuvant Cryoablation to Treat Bladder Cancer
    Official Title
    A Multi Center, Randomized, Parallel Controlled Study of Applying Transurethral Resection of Bladder Tumor With Adjuvant Cryoablation to Treat Bladder Cancer
    Study Type
    Interventional

    2. Study Status

    Record Verification Date
    October 2017
    Overall Recruitment Status
    Unknown status
    Study Start Date
    October 19, 2017 (Anticipated)
    Primary Completion Date
    October 30, 2018 (Anticipated)
    Study Completion Date
    December 31, 2018 (Anticipated)

    3. Sponsor/Collaborators

    Responsible Party, by Official Title
    Principal Investigator
    Name of the Sponsor
    Huashan Hospital
    Collaborators
    Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai Zhongshan Hospital, Shanghai 5th People's Hospital, Zhejiang Provincial People's Hospital

    4. Oversight

    Studies a U.S. FDA-regulated Drug Product
    No
    Studies a U.S. FDA-regulated Device Product
    No
    Data Monitoring Committee
    Yes

    5. Study Description

    Brief Summary
    The purpose of this study is to evaluate the safety and efficacy of applying cryoablation as an adjuvant therapy with TUR to treat bladder tumor.
    Detailed Description
    Bladder tumors are one of the most commonly diagnosed urinary tumors in the world. Worldwide, it has been estimated that 429,800 new cases of and 165,100 deaths due to bladder tumor occurred in 2012. Transurethral resection (TUR) is the gold-standard treatment for non-muscle invasive bladder cancer (NMIBC). In muscle-invasive bladder cancer, TUR also plays a vital role as a bladder-sparing procedure regardless of whether it is applied as a monotherapy or in combination with chemo-radiotherapy. Whether radical resection of a tumor is initially performed can be essential in the treatment of bladder tumors. Incomplete TUR influences a patient's prognosis, regardless of whether it is part of a NMIBC treatment or part of bladder-sparing trimodal therapy. However, the quality of TUR is one of the greatest concerns in the treatment of bladder tumor. After initial TUR, approximately 70% of patients exhibit incomplete resection re-staging TUR. Of these patients, 30% exhibit residual tumors at the resection site. To solve this problem, a second TUR 4-6 weeks after the initial TUR is recommended by the guidelines, and these repeated TURs detect residual tumors in 26-83% of cases. The investigators sought to identify other therapies that can be combined with TUR to eliminate residual tumors. As a minimally invasive method, cryotherapy has been widely used for urological tumors, including prostate tumor and kidney tumor. With respect to bladder tumors, cryotherapy remains in the exploration phase. Only a few studies of the use of computed tomography (CT)-guided percutaneous cryoablation for the treatment of bladder cancer have been reported. Unlike solid viscera, such as the prostate or kidney, the bladder exhibits the features of hollow viscera. Cryoablation through the transurethral approach could be possible if the safety of the procedure can be ensured. Our recent animal study conducted in a porcine model demonstrated the feasibility and safety of transurethral focal, full-thickness cryoablation. No perforations were observed during two eight-minute freeze cycles. Based on the success of transurethral cryoablation in animal experiments, the investigators performed this study to explore the safety and efficacy of cryoablation as an adjuvant therapy with TUR in the treatment of bladder tumors.

    6. Conditions and Keywords

    Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
    Urinary Bladder Neoplasms
    Keywords
    Bladder Cancer, Cryoablation

    7. Study Design

    Primary Purpose
    Treatment
    Study Phase
    Not Applicable
    Interventional Study Model
    Parallel Assignment
    Masking
    None (Open Label)
    Allocation
    Randomized
    Enrollment
    150 (Anticipated)

    8. Arms, Groups, and Interventions

    Arm Title
    TUR with Cryoablation
    Arm Type
    Experimental
    Arm Description
    Patients received TUR to treat bladder cancer and immediate cryoablation was applied on the tumor bed in order to eliminate possible residual tumor. Two or three cycles of freeze could be give to fully cover the lesion. One cycle last three to five minutes base on our previous animal experiments.
    Arm Title
    TUR with instant instillation
    Arm Type
    Active Comparator
    Arm Description
    Patients received TUR to treat bladder cancer and pirarubicin instillation was given within 24 hours after TUR. This is in accord with the current guideline.
    Intervention Type
    Procedure
    Intervention Name(s)
    Cryoablation
    Intervention Description
    Using a novel cryoablation unit to perform transurethral cryoablation on the tumor base after transurethral resection
    Intervention Type
    Drug
    Intervention Name(s)
    Epirubicin
    Intervention Description
    Epirubicin instillation should be give within 24 hours after initial TUR, this is accord with current guideline.
    Primary Outcome Measure Information:
    Title
    Residual tumor rate
    Description
    The investigators would perform reTUR 4-6 weeks after initial surgery to detect residual tumor
    Time Frame
    4-6 weeks after surgery
    Secondary Outcome Measure Information:
    Title
    Indwelling time
    Time Frame
    One month after surgery
    Title
    Adverse event rate
    Time Frame
    Through study completion, an average of 2 year

    10. Eligibility

    Sex
    All
    Minimum Age & Unit of Time
    18 Years
    Maximum Age & Unit of Time
    85 Years
    Accepts Healthy Volunteers
    No
    Eligibility Criteria
    Inclusion Criteria: Clinically diagnosed bladder tumor, stage T1 or T2 Number of lesions ≤ 3 Tumor size ≤ 3cm Exclusion Criteria: With other malignant diseases T3 or above Enlarged pelvic lymph node or distant metastasis Poor overall condition
    Central Contact Person:
    First Name & Middle Initial & Last Name or Official Title & Degree
    Shenghua Liu, Doctor
    Phone
    +86 021 52889999
    Email
    liushenghuafy@163.com
    Overall Study Officials:
    First Name & Middle Initial & Last Name & Degree
    Haowen Jiang, Doctor
    Organizational Affiliation
    Huashan Hospital
    Official's Role
    Study Director

    12. IPD Sharing Statement

    Plan to Share IPD
    Undecided
    Citations:
    PubMed Identifier
    26939677
    Citation
    Liu S, Zou L, Mao S, Zhang L, Xu H, Yang T, Jiang H, Ding Q. The safety and efficacy of bladder cryoablation in a beagle model by using a novel balloon cryoprobe. Cryobiology. 2016 Apr;72(2):157-60. doi: 10.1016/j.cryobiol.2016.02.007. Epub 2016 Mar 3.
    Results Reference
    background
    PubMed Identifier
    17826526
    Citation
    Hruby GW, Marruffo F, Ortiz J, Durak E, Edelstein A, Levi G, Landman J. Transurethral bladder cryoablation in the porcine model. Urology. 2007 Aug;70(2):391-5. doi: 10.1016/j.urology.2007.03.028.
    Results Reference
    background

    Learn more about this trial

    TURBt With Adjuvant Cryoablation to Treat Bladder Cancer

    We'll reach out to this number within 24 hrs